Seres Therapeutics, Inc. — Director's Dealing 2021

Jun 1, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Seres Therapeutics, Inc. (MCRB)
CIK: 0001609809
Period of Report: 2021-06-01

Reporting Person: Arkowitz David (Chief Financial Officer)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-06-01	Stock Options (right to buy)	$20.19	A	270000	Acquired	2031-05-31	Common Stock (270000)	Direct
2021-06-01	Restricted Stock Units	$	A	5000	Acquired		Common Stock (5000)	Direct

Footnotes

F1: This option will vest and become exercisable as to 25% of the shares on June 1, 2022. The remainder of the shares will vest and become exercisable in 12 equal quarterly installments thereafter.

F2: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock.

F3: 100% of the restricted stock units will vest and settle on June 15, 2022. The restricted stock units have no expiration date.